Review Article |
---|
Lijing L. Yan, Chaoyun Li, Jie Chen, J. Jaime Miranda, Rong Luo, Janet Bettger, Yishan Zhu, Valery Feigin, Martin O'Donnell, Dong Zhao, Yangfeng Wu
Although stroke incidence in high-income countries (HICs) decreased over the past four decades, it increased dramatically in low- and middle-income countries (LMICs). In this review, we describe the current status of primary prevention, treatment, and management of acute stroke and secondary prevention of and rehabilitation after stroke in LMICs. Although surveillance, screening, and accurate diagnosis are important for stroke prevention, LMICs face challenges in these areas due to lack of resources, awareness, and technical capacity.
Original Articles |
---|
Despite the increasing availability of head computerized tomography (CT) in resource-limited settings, it is unclear if brain-imaging-based diagnosis of stroke affects the outcomes in the absence of dedicated structures for acute stroke management
MPV17-related hepatocerebral mitochondrial DNA depletion syndrome (previously known as Navajo neurohepatopathy) was discovered in children in the Four Corner's region of New Mexico approximately 40 years ago. This disease is associated with a single missense mutation in exon 2 in the MPV17 gene. The syndrome has now been recognized world-wide. We find that huge quantities of neurotoxins were present in archived nervous tissues from such patients. Arsenic was increased 18 ×, cadmium ~ 10 ×, cobalt 2.5 × and manganese 2.3 ×; the largest increase was in mercury content 16,000 × compared to contemporaneous fresh-frozen normal nervous tissues.
During our practice of clinical neurological examination we frequently observed that patients, upon testing of cranial nerve VII, when instructed to "wrinkle their forehead" (to evaluate the innervation of the M. frontalis), seem to falsely "frown" (i.e. innervate the corrugator supercilii). Here, we set out to prospectively evaluate prevalence and characteristics of this phenomenon. Using a semi-structured questionnaire, we show that the majority of colleagues at our center shared our observation.
The continuous increase in the number of patients presenting with late-onset myasthenia gravis (LOMG) underscores the need for a better understanding of the clinical course and the establishment of an optimal therapeutic strategy. We aimed to clarify factors associated with clinical outcomes in LOMG.
Letters to the Editor |
---|
Oral extended release dalfampridine (FA) is a recently approved medication that blocks voltage-dependent potassium channels inhibiting functioning of axonal membranes. It results in improved conduction affecting ambulation in a subgroup of patients with multiple sclerosis (MS) [1–2].